Dysphagic patients needed for swallowing treatment

September 2013

Swallowing food and drink is part of our daily life and something that we do automatically. Sometimes people who suffer from brain injury (such as stroke) or neurodegenerative disease (such as Parkinson’s Disease) may have difficulties with swallowing which compromises their health.

One of the complications of a poor swallow is that food and drink may go down the wrong way and end up in the lungs, where it can cause chest infections. Swallowing problems termed ‘Dysphagia’ affect thousands of people every year. In fact, someone you know may have swallowing problems.

We are currently recruiting people with dysphagia for clinical studies assessing the effects of a swallowing treatment that uses electrical pharyngeal stimulation. Studies will involve visits to a clinical research facility for the electrical stimulation treatment and assessments of swallowing function.

If you are interested and would like further information regarding studies, please feel free to contact us using the details below:

Tel: 0161 820 9569

Email: chronic@phagenesis.com

Remuneration for your travel expenses and subsistence will be available.

This study has been approved by the MHRA and an NREC.

Update: The recruitment has finished.

 

Dr. Oern Stuge appointed Chairman of Phagenesis

May 2013

Manchester, UK – 21 March 2013 − Phagenesis®, the world’s leading company in the treatment of dysphagia, has appointed Dr. Oern Stuge, former senior executive at Medtronic and Abbott Laboratories, as Chairman.

The appointment comes as Phagenesis® secures its first revenues from its Phagenyx® treatment for dysphagia, launched in Q4 2012. Dysphagia is the inability to swallow safely, a condition caused by a variety of neurological conditions including stroke, Parkinson’s disease, cerebral palsy and multiple sclerosis.

Dr. Stuge brings to Phagenesis® his extensive experience at Medtronic Inc. in different positions including Senior Vice President & President Cardiac Surgery, President EMEA, Latin America, Canada & India, member of the Executive Committee & Operating Committee. He began his career as a practicing physician and has an MD from the University of Oslo, and an MBA from IMD in Lausanne.

Dr. Stuge said: “I am honoured to be invited to chair the board of Phagenesis®, whose innovative technology addresses a genuine unmet need. With the company’s technology we hope to help many patients: dysphagia is a debilitating condition that affects tens of millions worldwide who, until now, have not had access to a treatment that addresses the underlying neurological mechanism of the condition.”

Henry Hyde Thomson, outgoing chairman, commented: “In the three years I have served as Chairman, Phagenesis® has grown from a start-up to a revenue-generating company which has successfully launched its dysphagia treatment. Dr. Stuge’s extensive experience in the field of medical devices will help ensure Phagenesis’ continued success as it rolls out this vital treatment to patients and their carers around the world.”

Phagenyx® is the result of almost 20 years of R&D at the University of Manchester, UK. Treatment consists of a calibrated electrical signal delivered to the oropharynx (back of the throat) for 10 minutes a day for three consecutive days. Randomised controlled trials have shown that patients improve their swallowing function, and brain imaging shows that this is achieved through cortical remapping; a healthy part of the brain takes over the function of the damaged swallowing control centre.

Daniel Green, CEO, said: “Dr. Stuge’s appointment to the chairmanship is a great vote of confidence in Phagenesis® and the prospects for the Phagenyx® treatment, as we focus on the delivery of proven tools to help clinicians improve the lives of dysphagic patients in their care.”

Phagenesis expands Series B Financing to $17 million

May 2013

Manchester, UK – 22 May 2013 − Phagenesis, the world’s leading company in the treatment of dysphagia, has expanded its Series B financing to $17m. In 2011, Phagenesis announced a €7m Series B financing, led by Inventages Venture Capital.

The increased resources will be used to launch the Phagenyx® treatment, which received its CE Mark in 2012, in new territories and to expand clinical testing in new patient groups. Dysphagia is the inability to swallow safely, a debilitating condition that affects about half of stroke patients. Dysphagia can lead to the inhalation of solids or liquids followed by pneumonia. Current management of the condition includes tube-feeding patients, which can lead to a significant loss of quality of life.

The Phagenyx® treatment involves an electrical stimulus to the oropharynx (a region of the back of the throat) for 10 minutes a day for three consecutive days. Peer-reviewed, randomised clinical trials have shown that this treatment is safe and effective in improving participants’ safe swallowing ability.

Daniel Green, CEO of Phagenesis, said: “Our investors continue to show confidence in our ability to deliver this new technology to doctors to treat patients who might otherwise face a lifetime of tube feeding.” Oern Stuge, MD, recently appointed Chairman of Phagenesis®, said: “Dysphagia is one of the great unmet medical needs in the treatment of stroke, which healthcare systems around the world recognise as an increasingly important challenge both clinically and economically.”

Ashok Dhanrajgir, Director of Phagenesis® and a partner at Inventages, said: “Inventages remains a committed investor and major participant in the expanded Series B Financing, which will enable Phagenesis® to bring this important new technology to a wider patient population.”

Phagenesis wins Bionow Award for Healthcare Project of the Year 2012

December 2012

Manchester, UK – 3 December 2012 –Phagenesis Ltd, the global leader in the treatment of dysphagia, has won the Bionow Healthcare Project of the Year 2012 award. The award follows the launch of its first product, Phagenyx®, a medical device that treats dysphagia (difficulty swallowing) after stroke, in October.

Around half of stroke patients suffer with dysphagia1, a condition that is usually managed with puréed diet and tube feeding.

The award was sponsored by TRUSTECH, the North West NHS Innovation Service and entrants were judged on the impact of the product on the clinical problem it addresses, the quality of the product and the degree of innovation. The award was highly contested but on presenting the award Dr. Richard Deed, Innovation Unit Manager of TRUSTECH, said the judge’s decision was unanimous.

The award was collected by Dr. Conor Mulrooney, Chief Operating Officer at Phagenesis®.

Daniel Green, CEO of Phagenesis, said: “We are very pleased that Phagenesis® has won this award. We have seen so much development in the company over the past year. Dysphagia is an area of unmet medical need and we feel that this award reflects our device and the work that we are doing to address this.”

The annual awards dinner was attended by more than 280 executives from the biomedical sector.

Geoff Davison, CEO of Bionow, said: ‘The winners represent the cream of one of the leading clusters of biomedical businesses in the UK.”

http://stroke.ahajournals.org/content/36/12/2756.short

About Phagenesis®

Phagenesis® is developing the first clinically proven treatment for dysphagia, a debilitating and often lethal condition in which the patient’s ability to swallow is damaged. Dysphagia can lead to the inhalation of solids or liquids followed by pneumonia. Sufferers may face being fed through a tube indefinitely, reduced life expectancy and many are treated for depression. Phagenesis raised a £2 million Series A financing in 2010 and a €7m financing in 2011.

About Bionow

Bionow is a specialist business development and services company focused on the biomedical industry in the North of England and has over 160 members.

Phagenesis wins CE mark for Phagenyx® to treat dysphagia

October 2012

Manchester, UK – 16th October 2012 -–Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that its treatment system Phagenyx®, the world’s first treatment for acute dysphagia following stroke, has been awarded a CE Mark.

Dysphagia, the inability to swallow safely, is a debilitating condition that affects about half of all stroke patients. Dysphagia frequently leads to potentially life-threatening pneumonia and the surgical implantation of a PEG tube to allow a patient to be fed indefinitely through the abdomen wall.

The CE Mark paves the way for Phagenyx® to be launched in Europe, where there are more than 1 million strokes per year.

The Phagenyx® treatment system delivers a calibrated electrical signal to the back of the throat (oropharynx) for 10 minutes a day for three consecutive days. This protocol has shown to lead to a clinically and statistically significant improvement in swallowing function in a majority of dysphagia patients. Phagenyx® is the result of almost 20 years of research and development, led by Professor Shaheen Hamdy of the Salford Royal Hospital and the University of Manchester.

Daniel Green, CEO of Phagenesis, said: “The Phagenyx® treatment system allows doctors, nurses and speech and language therapists to alleviate the suffering of hundreds of thousands of stroke patients across the world. The CE marking will allow the system to be rolled out across Europe and other territories.”

Phagenesis launches first treatment for acute dysphagia

October 2012

Barcelona – 25th October 2012 – Phagenesis today launches the world’s first approved treatment for acute dysphagia following stroke.

The Phagenyx® system delivers calibrated electrical stimulus to the throat (oropharynx) for 10 minutes a day for three consecutive days to patients who suffer from dysphagia – the inability to swallow safely – a debilitating condition that affects about half of all stroke patients[1]. Randomised controlled clinical trials show that this protocol leads to statistically significant improvements in patients’ swallowing function.

Phagenesis also announced its first sales of the Phagenyx® system, in a transaction worth seven figures, to Modern Pharmaceutical Company (MPC), a leading distributor in the Middle East at the annual congress of the European Society for Swallowing Disorders (ESSD) in Barcelona, Spain. Initial markets for Phagenyx® will be the UK and the UAE.

Daniel Green, CEO of Phagenesis®, said: “Within the last few months, the team has worked tirelessly to get the product to where it is today. By bringing this product to market, we are providing physicians with the tools they need to treat dysphagia and alleviate the suffering of many stroke patients.”

The Phagenyx® system is the result of almost 20 years work by Professor Shaheen Hamdy at the University of Manchester, UK. Phagenesis®, a Manchester company, was formed in 2007 to turn Professor Hamdy’s work into technology suitable for everyday use in hospitals.

Dysphagia significantly increases the risk of aspiration pneumonia that can lead to an extended hospital stay, transfer to intensive care, expensive drug treatment and risk of death. Recovery can take months and some patients never regain their swallowing function. Clinical trials with the electrical stimulation delivered by Phagenyx® have shown not only a reduction in the level of aspiration (inhaled liquids or solids) that can lead to life-threatening pneumonia, but also a reduction of 5 days in hospital stays for stroke patients. Based on the reduction in hospital stay, studies show that Phagenyx® is cost saving as well as clinically beneficial.